Compare Medtronic PLC (MDT) vs Palantir Technologies Inc (PLTR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medtronic PLC vs Palantir Technologies Inc — how do they compare? Medtronic PLC trades at $87.9 (market cap $112.24B), while Palantir Technologies Inc trades at $200.1 (market cap $477.68B). The key difference: Palantir Technologies Inc is far larger — about 4.3× Medtronic PLC's market cap, and Medtronic PLC pays a 3.28% dividend while Palantir Technologies Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Medtronic PLC for 63 Days and Palantir Technologies Inc for 78 Days on average.
| MDT | PLTR | |
|---|---|---|
Market Cap | $112.24B | $477.68B |
Volume | 105,663,236 | 41,744,992 |
Sector | Health | Technology |
52-Week High | $105.35 | $207.18 |
52-Week Low | $73.75 | $107.27 |
Typical Hold Time | 63 Days | 78 Days |
Enterprise Value | $131.58B | $468.48B |
Dividend Yield | 3.28% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Medtronic (MDT) trades at $85.51, down 1.81% on the day, showing bearish technical signals despite strong fundamental performance. The company has beaten earnings estimates for three consecutive quarters with Q3 2026 results pending, while maintaining robust profitability margins of 65% gross and 14% net. Recent news highlights the company's 49-year dividend growth streak and new product approvals, though technical indicators show selling pressure with the stock trading near support at $85.
MDT presents a compelling value opportunity with a 3.2% dividend yield and 14% upside to the $97.80 consensus target, though near-term technical weakness and increasing debt levels warrant caution. The company's consistent earnings beats and medical device market leadership support long-term growth, while regulatory approvals for new systems provide catalysts.
Palantir (PLTR) trades at $194.04, up 1.02% with a bullish technical outlook and strong fundamental momentum. The stock shows robust revenue growth of 56.2% in 2025, reaching $4.48 billion, with net income surging to $1.63 billion. Recent partnerships with Armada for sovereign AI infrastructure and consistent earnings beats highlight operational strength, though valuation metrics remain elevated with a P/E of 165.91.
The outlook remains positive with analyst consensus at Buy (53.84%) and a $191.69 price target. Key opportunities include AI platform expansion and commercial customer growth to 870, while risks involve high valuation sensitivity and competitive pressures. The stock trades near recent highs with support at $191 and resistance at $195.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Medtronic PLC
One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →About Palantir Technologies Inc
Palantir Technologies provides organizations with solutions to manage large disparate data sets in an attempt to gain insight and drive operational outcomes. Founded in 2003, Palantir released its Gotham software platform in 2008, which focuses on the government intelligence and defense sectors. Palantir expanded into various commercial markets with its Foundry software platform in 2016 with the intent of becoming the data operating system for companies and industries. The Denver company had 125 customers as of its initial public offering and roughly splits its revenue between commercial and government customers.
Read more on PLTR →
